Lisinopril with hydrochlorothiazide
Brand names: Zestoretic, Caralpha
This is a fixed-dose combination of the ACE inhibitor lisinopril with the thiazide diuretic hydrochlorothiazide, used to treat essential hypertension in patients whose blood pressure is not adequately controlled on a single agent.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Lisinopril inhibits angiotensin-converting enzyme to reduce angiotensin-II-mediated vasoconstriction and aldosterone secretion, while hydrochlorothiazide increases renal sodium and water excretion; the combination lowers blood pressure through complementary mechanisms.
Prescribing in practice
- The combination is contraindicated in pregnancy and in patients with previous ACE-inhibitor-associated angioedema, and the ACE inhibitor component should be stopped if angioedema occurs.
- Combining an ACE inhibitor with a thiazide affects potassium in opposing directions and can also cause hyponatraemia, so electrolytes need monitoring rather than being assumed to balance out.
- There is a risk of first-dose or volume-depletion hypotension, and hydrochlorothiazide carries cautions around gout, photosensitivity and a small increased non-melanoma skin cancer risk.
Monitoring
Monitor renal function, serum sodium and potassium and blood pressure before treatment and after initiation or any dose change.
Counselling the patient
- Seek emergency help if your face, lips, tongue or throat swell or you have difficulty breathing.
- Do not use this medicine in pregnancy; tell your doctor immediately if you become pregnant.
- Use sun protection and report dizziness, cramps or a dry cough.
Evidence & guidelines
Combining an ACE inhibitor with a thiazide diuretic for hypertension uncontrolled on monotherapy is consistent with NICE hypertension guidance and established combination-therapy evidence.
Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines